Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Cystic Fibrosis
Interventions
DRUG

Lucinactant first

lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs

DRUG

Placebo first

6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours

Trial Locations (1)

27599

University of North Carolina, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

collaborator

Windtree Therapeutics

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT00934362 - Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease | Biotech Hunter | Biotech Hunter